Adverse outcomes from the use of older donor hearts in cardiac transplant recipients: The pros and cons of expanded donor criteria

Journal of the American College of Cardiology

Volumn 43, Issue 9, 2004, Pages 1562-1564

  Eisen, Howard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AGE DISTRIBUTION; GRAFT REJECTION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NOTE; ORGAN DONOR; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECIPIENT; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 2342443073     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.005     Document Type: Editorial

References (13)

1. Hosenpud J.D., Bennett L.E., Keck B.M., Fiol B., Boucek M.M.J., Novick R.J. The Registry of the International Society of Heart and Lung Transplantation Sixteenth official report - 1999. J Heart Lung Transpl. 18:1999;611-626
2. Lietz K, John R, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list: implications for donor selection criteria. J Am Coll Cardiol 2004;43:1553-61.
3. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 66:1998;507-515
4. Grande A.M., Rinaldi M., D'Armini A.M., et al. Orthotopic heart transplantation Standard versus bicaval technique. Am J Cardiol. 85:2000;1329-1333
5. Zaroff J.G., Rosengard B.R., Armstrong W.F., et al. Consensus conference report Maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation. 106:2002;836-841
6. Mather P., Jeevanandam V., Eisen H.J., et al. Functional and morphologic adaptation of undersized donor hearts following cardiac transplantation. J Am Coll Cardiol. 26:1995;737-742
7. Griepp R.B., Stinson E.B., Clark D.A., et al. The cardiac donor. Surg Gynec Obstet. 133:1971;792-798
8. Hoecher K., Young J.B., McCarthy P.M., Smedira N., Price L.L., Stewart K.W. Long term mortality and morbidity with use of older donors in cardiac transplantation A single center experience. Transplantation. 65:1998;S104
9. McCarthy J.F., McCarthy P.M., Massad M.G., et al. Risk factors for death after heart transplantation Does a single center experience correlated with multicenter registries? Ann Thorac Surg. 65:1998;1564-1569
10. Tuzcu E.M., Kapadia S.R., Tutar E., et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults Evidence from ultrasound. Circulation. 103:2001;2705-2710
11. Mehra M.R., Prasad A., Uber P.A., Park M., Scoot R. The impact of explosive brain death on the genesis of cardiac allograft vasculopathy; an intravascular ultrasound study. J Heart Lung Transplant. 19:2000;522-528
12. Kobashigawa J., Wener L., Currier J.W., Yeatman L., Cassem J., Tobis J. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant. 19:2000;546-550
13. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med. 349:2003;847-858